Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
regulatory T cells
Biotech
Nektar eczema asset 'checked all of the boxes' in phase 2
The results set rezpeg up to become “a preferred second-line therapy” in atopic dermatitis.
Darren Incorvaia
Feb 10, 2026 10:55am
Quell halts transplant trial to focus on 'chill not kill' Treg
Feb 5, 2026 6:00am
JPM26: Chugai chases new science and name recognition
Jan 16, 2026 5:28am
Fierce's favorite research stories of 2025
Dec 23, 2025 5:00am
Nektar claims ph. 2 alopecia success after excluding 4 patients
Dec 16, 2025 5:05pm
Zag Bio emerges with $80M funding for Tregs diabetes candidate
Oct 28, 2025 7:00am
